Valuation ORIC Pharmaceuticals, Inc. Börse Stuttgart
Stocks
4TZ
US68622P1093
Biotechnology & Medical Research
|
Real-time Estimate
Tradegate
15:39:31 2026-08-31 EDT
|
5-day change | 1st Jan Change | ||
| 11.03 EUR | -3.01% |
|
-5.68% | +64.78% |
Company Valuation: ORIC Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 578.9 | 264.8 | 501.9 | 569.5 | 796.6 | 1,372 | - | - |
| Change | - | -54.26% | 89.55% | 13.47% | 39.89% | 72.27% | - | - |
| Enterprise Value (EV) | 578.9 | 264.8 | 266.8 | 569.5 | 751 | 1,372 | 1,372 | 1,372 |
| Change | - | -54.26% | 0.78% | 113.42% | 31.87% | 82.74% | 0% | 0% |
| P/E | -7.1x | -2.62x | -4.69x | -4.41x | -5.56x | -8.72x | -8.04x | -7.15x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0.3x | 0.4x | 0.66x | 0.3x | -2.66x | -0.95x | -0.6x |
| Capitalization / Revenue | - | - | - | - | - | - | - | 448x |
| EV / Revenue | - | - | - | - | - | - | - | 448x |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -8.5x | -8.29x | -9.6x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -7.7x | -6.73x | -5.75x |
| EV / FCF | -0x | -0x | -0x | -0x | -0x | -10.1x | -8.12x | -6.3x |
| FCF Yield | -10.4% | -29.2% | -17.2% | -20% | -14% | -9.91% | -12.3% | -15.9% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.07 | -2.25 | -1.96 | -1.83 | -1.47 | -1.518 | -1.646 | -1.852 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | 3.064 |
| EBITDA 1 | -77.97 | -90.8 | -109.7 | -141.8 | -141.8 | -161.4 | -165.6 | -143 |
| EBIT 1 | -78.87 | -91.77 | -110.8 | -142.9 | -143 | -178.2 | -203.9 | -238.7 |
| Net income 1 | -78.72 | -89.12 | -100.7 | -127.8 | -129.5 | -165.6 | -196.9 | -239.6 |
| Net Debt | - | - | -235 | - | -45.67 | - | - | - |
| Reference price 2 | 14.70 | 5.89 | 9.20 | 8.07 | 8.18 | 13.24 | 13.24 | 13.24 |
| Nbr of stocks (in thousands) | 39,382 | 44,953 | 54,552 | 70,567 | 97,389 | 103,653 | - | - |
| Announcement Date | 3/21/22 | 3/16/23 | 3/11/24 | 2/18/25 | 2/23/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 20.59x | 7.25x | 14.66x | 1.42% | 69.54B | |
| 36.89x | 9.62x | 29.41x | 0.04% | 64.97B | |
| 30.69x | 6.58x | 17.2x | -.--% | 26.51B | |
| -72.56x | 13.98x | -67.43x | -.--% | 25.89B | |
| -15.61x | 5.94x | -7.46x | -.--% | 25.64B | |
| 58.27x | 21.67x | 43.95x | 0.26% | 20.22B | |
| 27.27x | 5.11x | 16.98x | -.--% | 19.98B | |
| 1415.29x | 39.34x | 858.54x | -.--% | 15.69B | |
| 16.84x | 5x | 11.66x | -.--% | 13.49B | |
| Average | 168.63x | 12.72x | 101.95x | 0.19% | 31.33B | |
| Weighted average by Cap. | 94.04x | 10.79x | 57.82x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ORIC Stock
- 4TZ Stock
- Valuation ORIC Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
